Danielle Lauzon is a partner in Goodwin’s Technology Companies & Life Sciences group and leader of the firm’s Business Law Department in Boston. Ms. Lauzon represents issuers in connection with the public offering and private placement of equity securities, and has represented companies as well as venture capital and private equity firms in numerous venture capital financings and recapitalizations. From 2007 through 2012, Ms. Lauzon was recognized as Massachusetts Super Lawyer “Rising Star” for her work representing private and public companies on general corporate and securities law and mergers and acquisitions.

Ms. Lauzon acts as co-chair of Goodwin’s PropSci practice which is focused on supporting the intersection of real estate and life sciences. Through our industry and practice area connectivity, and leveraging our existing reputation as leaders in the real estate and life sciences spaces, Goodwin provides clients integrated and innovative services that adapt along with their needs.

Ms. Lauzon currently serves on Goodwin’s Partnership Committee for the firm’s Boston office.





Ms. Lauzon’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences and healthcare information technology services industries. Her recent representations include:

  • BELLUS Health in its $40 million public offering 
  • iTeos Therapeutics in its $201.1 million initial public offering
  • AlloVir, Inc. in its $317.7 million initial public offering
  • Unum Therapeutics in its $104.4 million private placement of common stock
  • iTeos Therapeutics in its $125.3 million Series B financing
  • ElevateBio in its $170 million Series B financing
  • Blueprint Medicines Corporation in its $325 million follow-on offering
  • Unum Therapeutics in its acquisition of KIQ
  • Zafgen in its definitive merger agreement with Chrondrial Therapeutics
  • resTORbio, Inc. in its reverse merger with Adicet
  • Semma Therapeutics in its $950 million sale to Vertex 
  • Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
  • AMRI in its $1.7 billion (enterprise value) sale to affiliates of The Carlyle Group and GTCR LLC
  • AMRI in its $358 million acquisition of Euticals and $174 million acquisition of Gadea Pharmaceutical Group
  • Blueprint Medicines in its $345 million, $230 million and $125 million follow-on offerings
  • Zafgen in its $60 million underwritten public offering
  • resTORbio, Inc. in its $97.8 million initial public offering
  • Unum Therapeutics in its $69.2 million initial public offering and $5 million concurrent private placement
  • ProQR Therapeutics in its $75 million underwritten public offering
  • ProQR Therapeutics in its $20 million underwritten public offering and concurrent registered direct offering
  • Aerpio Pharmaceuticals in its $40 million underwritten public offering and uplisting to Nasdaq
  • Aerpio Pharmaceuticals in its $40 million reverse merger and private placement
  • Aerpio Pharmaceuticals in its $75 million at-the-market program with Cantor Fitzgerald & Co.
  • Allurion Technologies in its $27 million Series C financing
  • .406 Ventures in its investments in Wellist and Virtudent
  • Alector LLC in its Series A, Series B, Series C, and Series D financings
  • Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
  • Unum Therapeutics in its $65 million Series B financing
  • ProQR Therapeutics N.V. in its $97.5 million initial public offering
  • Conformis in its $20 million follow-on offering with Cowen and Canaccord Genuity
  • Conformis in its $50 million offering of stock with Canaccord Genuity
  • AbileTo, Inc. in its Series A, Series B, Series C, and Series D financings
  • Zalicus Inc. in its sale to Epirus Biopharmaceuticals
  • Moderna Therapeutics in the closing of a $110 million financing round
  • Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
  • Phase Forward in its sale to Oracle Corporation
Professional Activities
Ms. Lauzon is a member of the Massachusetts and Boston Bar Associations.
Professional Experience

Prior to joining Goodwin, Ms. Lauzon was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.


Ms. Lauzon has been recognized by The Legal 500 U.S. for her work in the life science industry, and from 2007 through 2012, she was recognized as a Massachusetts Super Lawyer "Rising Star" by Law & Politics and Boston magazine. In law school, Ms. Lauzon was a member of the Villanova Law Review.

In The News









J.D., 2000
Villanova University School of Law

(magna cum laude, Order of the Coif)

B.A., 1997
University of Michigan



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique